Endocannabinoid Levels May Be Disrupted Early in Multiple Sclerosis

Newly diagnosed MS patients in acute relapse showed a non-significant trend toward lower plasma anandamide (AEA) compared to healthy controls (mean difference -5.95 ng/ml, p=0.098). In teriflunomide-treated patients, AEA and 2-AG were strongly positively correlated (r=0.882), a pattern not seen in other groups. Quality of life was significantly lower in newly diagnosed patients.

Cross-sectional study comparing plasma endocannabinoid levels (AEA and 2-AG) in 10 healthy controls, 10 newly diagnosed relapsing-remitting MS patients in acute relapse, and 10 teriflunomide-treated RRMS patients in remission. Clinical assessments included MMSE and SF-36.

The endocannabinoid system is thought to play a role in MS through its involvement in immune regulation and neuroprotection. This small study provides early evidence that endocannabinoid levels may be disrupted in MS, potentially offering a biomarker or therapeutic target.

Interest in cannabinoid-based therapies for MS has grown, driven partly by patient self-medication with cannabis for spasticity and pain. Understanding how the endocannabinoid system changes during MS could inform whether and how cannabinoid therapies might complement existing treatments.

Very small sample (10 per group) with wide variability. The AEA difference did not reach statistical significance. Cross-sectional design at a single time point. Plasma endocannabinoid levels may not reflect central nervous system levels. No control for lifestyle factors that affect endocannabinoid levels.